An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty
Phase of Trial: Phase IV
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 06 Jun 2017 Planned initiation date changed from 22 May 2017 to 9 Jun 2017.
- 18 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 1 May 2017.